Literature DB >> 3958764

Pancreatic carcinoma and Trousseau's syndrome: experience at a large cancer center.

R Pinzon, B Drewinko, J M Trujillo, V Guinee, G Giacco.   

Abstract

It is common belief that carcinoma of the pancreas has an inherent and unique ability to induce a hypercoagulable diathesis that leads to clinically significant thrombosis. We evaluated 130 consecutive patients with adenocarcinoma of the pancreas to document the incidence and the predisposing factors related to the postulated increased association of thromboembolic disorder (TED) and pancreatic carcinoma. Only nine such patients (6.9%) demonstrated TED complications of the classical Trousseau syndrome. In these instances, the location of the tumor and its mucin-producing potential were significant predisposing factors. In our series, TED was usually associated with tumors of the body and tail, which had a greater likelihood to be mucinogenic as compared with those localized to the head of the pancreas. Routine tests for hemostasis were not helpful in predicting the development of TED except, perhaps, for decreased platelet counts. Therefore, we believe that the relationship between cancer of the pancreas and TED should be de-emphasized since it is neither unique nor especially common to pancreatic carcinoma and since it may be frequently encountered in other varieties of visceral malignancies of the cancer patient population.

Entities:  

Mesh:

Year:  1986        PMID: 3958764     DOI: 10.1200/JCO.1986.4.4.509

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  12 in total

Review 1.  Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients.

Authors:  Ana T Rocha; Edison F Paiva; Arnaldo Lichtenstein; Rodolfo Milani; Cyrillo Filho Cavalheiro; Francisco H Maffei
Journal:  Vasc Health Risk Manag       Date:  2007

2.  Acute nontraumatic splenic infarctions at a tertiary-care center: causes and predisposing factors in 123 patients.

Authors:  Mougnyan Cox; Zhenteng Li; Vishal Desai; Lauren Brown; Sandeep Deshmukh; Christopher G Roth; Laurence Needleman
Journal:  Emerg Radiol       Date:  2016-01-21

3.  Management and prevention of thromboembolic events in patients with cancer-related hypercoagulable states: a risky business.

Authors:  F P Sarasin; M H Eckman
Journal:  J Gen Intern Med       Date:  1993-09       Impact factor: 5.128

Review 4.  Pancreatic cancer and thromboembolic disease, 150 years after Trousseau.

Authors:  David Ansari; Daniel Ansari; Roland Andersson; Åke Andrén-Sandberg
Journal:  Hepatobiliary Surg Nutr       Date:  2015-10       Impact factor: 7.293

5.  Thromboembolism in gastrointestinal cancers.

Authors:  Eric D Tetzlaff; Jonathan D Cheng; Jaffer A Ajani
Journal:  Gastrointest Cancer Res       Date:  2008-11

Review 6.  Assessing risk of venous thromboembolism in the patient with cancer.

Authors:  Alok A Khorana; Gregory C Connolly
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

7.  Heparin-induced thrombocytopenia among patients of a comprehensive cancer center.

Authors:  Weixin Wu; Kelly Merriman; Amr Nabaah; Nikhil Seval; Vahid Afshar-Kharghan; Sai-Ching J Yeung
Journal:  SAGE Open Med Case Rep       Date:  2014-07-31

8.  Clinical features of patients with lung cancer accompanied by thromboembolism or disseminated intravascular coagulation.

Authors:  Nobuhiro Kanaji; Hitoshi Mizoguchi; Takuya Inoue; Akira Tadokoro; Naoki Watanabe; Tomoya Ishii; Yasunori Tojo; Masahiro Yamaguchi; Norimitsu Kadowaki
Journal:  Ther Clin Risk Manag       Date:  2018-08-01       Impact factor: 2.423

Review 9.  The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues.

Authors:  Elena Campello; Anton Ilich; Paolo Simioni; Nigel S Key
Journal:  Br J Cancer       Date:  2019-07-22       Impact factor: 7.640

10.  Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.

Authors:  Hye Won Chung; Jong-Baeck Lim
Journal:  J Transl Med       Date:  2014-04-21       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.